Quarterly ResultMay 12, 2026, 04:38 PM
Harvard Bioscience Q1 Revenue $20.76M, Net Loss $(3.42M); Reverse Split
AI Summary
Harvard Bioscience reported Q1 2026 revenue of $20.755 million, a decrease from $21.774 million in the prior year. The company's net loss significantly improved to $(3.424) million, or $(0.77) per share, compared to a net loss of $(50.340) million, or $(11.42) per share, in Q1 2025, primarily due to the absence of a goodwill impairment charge. Additionally, Harvard Bioscience completed a 1-for-10 reverse stock split in March 2026, initiated a restructuring plan in January 2026, and refinanced its debt with a new $45.0 million Loan and Security Agreement in December 2025.
Key Highlights
- Q1 2026 revenue was $20.755 million, down from $21.774 million in Q1 2025.
- Q1 2026 net loss was $(3.424) million, a significant improvement from $(50.340) million in Q1 2025.
- Basic and diluted loss per share for Q1 2026 was $(0.77), compared to $(11.42) in Q1 2025.
- A 1-for-10 reverse stock split was effective on March 13, 2026.
- Q1 2025 included a $47.951 million goodwill impairment charge, with no such charge in Q1 2026.
- Net cash used in operating activities was $(662) thousand in Q1 2026, compared to $2,986 thousand provided in Q1 2025.
- Entered into a new $45.0 million Loan and Security Agreement in December 2025.
- Initiated "Project Viking" restructuring plan in January 2026.